Seminar | Advancing Translational and Clinical Research

Hear Dr. Akil Merchant, MD, describe how research teams from the University of Southern California use Imaging Mass Cytometry™ to assess circulating tumor cells in the blood and analyze immune cells within the tumor microenvironment.

In this recorded live seminar, Merchant discusses:

how Imaging Mass Cytometry was integrated with the HD-SCA assay to study the role of CTCs in prostate and breast cancer

the simultaneous analysis of multiple markers to identify TREG cells within the tumor microenvironment

the characterization of immune infiltrate in Hodgkin’s lymphoma

Researchers in Merchant’s lab are investigating how tumor cells interact with their microenvironment and how this interaction contributes to the development and maintenance of cancer. They are studying how immune cells are trafficked into the tumor space and how immune cells can be harnessed to treat cancer. They are also interested in signaling pathways in cancer cells that confer resistance to chemotherapy. Merchant is a practicing hematologist and oncologist at USC Norris Comprehensive Cancer Center. He also participates in several clinical trials for patients with various cancers.

Akil Merchant, MDAssistant Professor of Medicine
Keck School of Medicine
University of Southern California

Related Applications

Related Products

Tags

Seminar | Uncovering Cellular Networks

Analysis of Tissue Ecosystems in Health and Disease by Imaging Mass Cytometry

Media

Assessment of cell-to-cell interactions and the tissue ecosystem by Imaging Mass Cytometry supports the Bodenmiller lab’s goal of using precision medicine to revolutionize disease treatment.

Hear Bernd Bodenmiller, PhD, describe how this new approach provides researchers with an unprecedented view of complex cellular phenotypes and their relationships in the context of the tissue microenvironment.

In this recorded live seminar, Bodenmiller discusses:

how Imaging Mass Cytometry™ empowers a multiplexed tissue view from molecules to morphology

the development of histoCAT™ software and how it enables deep analysis of cell type and cellular social networks

the use of Imaging Mass Cytometry to assess cellular heterogeneity and identify a variety of phenotypes in breast cancer samples

an approach to profiling of tumor sphere cultures

Bodenmiller’s lab develops experimental and computational methods to unravel regulatory systems on the single-cell level that underlie cancer development. His group’s goal is to develop methods based on CyTOF® technology to quantitatively analyze trans-cellular circuits. Based on the mass cytometry data, they model and analyze how complex cell phenotypes in tumors are controlled, with the hope that this will enable targeted modulation that interferes with tumor development.

Related Applications

Related Products

Tags

Webinar | Maximizing Human Immune Monitoring with Mass Cytometry

Integrating deep immune profiling into translational research studies

Media

Mass cytometry expert Adeeb Rahman, PhD, describes the basics of mass cytometry and how it is used today to support the full service immune monitoring program at the Icahn School of Medicine at Mount Sinai.

In this recorded webinar, Rahman shares how he has successfully integrated deep immune profiling with mass cytometry into translational research in multiple disease areas including cancer, infectious disease and allergy, enabling immune landscape mapping and discovery of disease-specific immune cell signatures.

Michelle Poulin, PhD, of Fluidigm, describes the development of the Maxpar® Human Immune Monitoring Panel Kit, designed to enable deep immune profiling of human PBMC in a single tube. Poulin presents an overview of the 29-marker mass cytometry panel as well as data showing repeatability, reproducibility and performance verification when the panel is used with frozen PBMC samples.

Webinar | Understanding the Immune Composition

Hear Dr. Kurt Schalper describe how research performed at the Translational Immuno-Oncology Laboratory at Yale Cancer Center uses Imaging Mass Cytometry™ (IMC™) as one way to open new opportunities for biomarker discovery and identification of targets that can lead to patient selection for novel immunostimulatory therapies.

In this recorded webinar, Schalper discusses:

how his group deciphers the tumor microenvironment and its role in immuno-oncology using highly multiplexed panels

Please join us for the webinar and an in-depth Q&A session that follows.

Dr. Schalper is currently Assistant Professor of Pathology and the Director of the Translational Immuno-Oncology Laboratory at the Yale Cancer Center. The Translational Immuno-Oncology lab is devoted to producing and supporting high-quality translational research in immuno-oncology through standardized analyses of biomarkers and cross-integration with other Yale resources.

Related Applications

Related Products

Characterizing the molecular pacemakers of pregnancy

Media

Stanford researchers describe how their integration of CyTOF® mass cytometry analysis with other omic approaches revealed the existence of an immune clock during human pregnancy.

In this recorded webinar, Dr. Brice Gaudilliere, MD, PhD, and Nima Aghaeepour, PhD, both of Stanford University School of Medicine, describe how they characterized the molecular pacemakers of pregnancy by integrating CyTOF® mass cytometry analysis and other omic approaches on blood samples collected throughout pregnancy.

The maintenance of pregnancy relies on a finely tuned immune balance between tolerance to the fetal allograft and protective mechanisms against invading pathogens. Demonstrating the chronology of immune adaptations to a term pregnancy provides the framework for future studies examining deviations implicated in pregnancy-related pathologies including preterm birth and preeclampsia.

Gaudilliere presents data demonstrating that these adaptations are precisely timed, reflecting an immune clock of pregnancy in women delivering at term. An elastic net model with prior Bayesian distributions extracted from literature-based knowledge of the immune was used to develop a predictive model of interrelated immune events that accurately captured the chronology of pregnancy.

Aghaeepour describes how the immunological dataset derived from the mass cytometry analysis was integrated with other omic datasets collected simultaneously at each time point, including data from the transcriptome, microbiome, proteome and metabolome. He also presents a novel computational approach combining all available omic datasets into a predictive model that reveals unique interactions between the different pacemakers of pregnancy.

Related Applications

Related Products

See the Future of Tissue Imaging

Introducing the Hyperion™ Imaging System

Media

Watch Chris Linthwaite, President and CEO of Fluidigm, introduce the Hyperion™ Imaging System at the Future of Imaging announcement event held on October 24, 2017, in Toronto, Canada.

During this 90-minute program you will also hear three leading researchers share their insights and experiences with this revolutionary new approach to tissue imaging in the context of their own translational research programs.

Previously viewed live by researchers from around the world, this exciting program is now available to view on-demand.

The Hyperion Imaging System significantly expands the number of protein biomarkers that can be simultaneously detected from tissues and tumors as compared to results from standard fluorescent immunohistochemistry (IHC) methods. With the potential to revolutionize disease research and change the way diseases are treated and ultimately cured in the future, this new approach provides researchers with an unprecedented view of complex cellular phenotypes and their relationships in the context of the tissue microenvironment.

Presenters:

A New View: Empowering a Revolution in Tissue Imaging Chris Linthwaite
President and CEO
Fluidigm

Uncovering Cellular Social Networks: Analysis of Tissue Ecosystems in Health and Disease by Imaging Mass Cytometry Bernd Bodenmiller, PhD
Assistant Professor
Institute of Molecular Life Sciences
University of Zurich

Watch these highlighted talks from the June 9 Summit

Join Us

More than 200 scientists from around the world gathered in Boston on June 9 for our 6th Annual Mass Cytometry Summit to share research findings, discuss advances and develop new collaborations. We are grateful to the researchers below who have graciously agreed to share their presentations with the mass cytometry community.

Related Applications

Related Products

Mass Cytometry in Focus

Hear what researchers are saying about the power of mass cytometry

Media

Enabling high-parameter studies, mass cytometry has quickly become a mainstay in basic and translational research laboratories around the world. In this video researchers share how mass cytometry is powering new insights in health and disease.

Related Applications

Related Products

Finding Pathologic T Cells in Rheumatoid Arthritis by Mass Cytometry

Researchers identify a unique population of pathologic CD4+ T cells

Media

Researchers identify a unique population of pathologic CD4+ T cells in both blood and synovial fluid using mass cytometry

In this video, Dr. Deepak Rao, MD, PhD, of Brigham and Women’s Hospital presents his recent research using mass cytometry and multidimensional flow cytometry to identify key pathologic T cell populations in the synovial fluid of subjects with rheumatoid arthritis.

Determining the pathologic functions of T cells that infiltrate target tissues remains a central challenge in autoimmune diseases. In this video, Dr. Deepak Rao, MD, PhD, of Brigham and Women’s Hospital describes recent work, published in Nature, identifying a unique population of pathologic CD4+ T cells, called T peripheral helper (TPH) cells, that is markedly expanded in the joints of subjects with rheumatoid arthritis (RA). Rao and colleagues used mass cytometry and multidimensional flow cytometry to interrogate T cell populations in synovial tissue and blood from research subjects with RA, a chronic immune-mediated arthritis that affects up to 1% of the population.

Rao and colleagues propose that PD-1hiCXCR5- T cells represent a TPH cell population, analogous to TFH cells, that supports B cell responses in pathologically inflamed nonlymphoid tissues. Given their marked expansion in RA joints, these cells may be important in driving pathologic B cell responses and autoantibody production within the inflamed target tissue.

Michelle Poulin, PhD, of Fluidigm provides a brief overview of mass cytometry, the high-parameter, single-cell analysis technology used by Rao in his research.